Pulmatrix, Inc. Banner Image

Pulmatrix, Inc. has reached its limit for free report views

Work for Pulmatrix, Inc.? Upgrade Your Profile and unlock all your annual reports.

Pulmatrix, Inc.

  • Ticker PULM
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Pulmatrix, Inc. Logo Image
  • 11-50 Employees
  • Based in Lexington, Massachusetts
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSEā„¢ technology. The Company's proprietary product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonaryMore aspergillosis ("ABPA"), and PUR1800, a narrow spectrum kinase inhibitor in lung cancer. Pulmatrix's product candidates are based on iSPERSEā„¢, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.
Pulmatrix, Inc.

Most Recent Annual Report

Pulmatrix, Inc.
MOST RECENT 2021 Annual Report and Form 10K

Report Locked. Pulmatrix, Inc. has reached its limit for free report views.

Older/Archived Annual Reports